MedTrace Logo

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2016-02-09

No results posted yet for this study

Summary

The purpose of this protocol is to provide continued acess to immunosuppressive medications to subjects from the completed/closed trial ITN005CT (NIS01,NCT00014911). THIS PROTOCOL DOES NOT PROVIDE MEDICINES TO DIABETES PATIENTS WHO DID NOT PARTICIPATE IN ITN005CT.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

Sirolimus

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

DRUG

Tacrolimus

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

DRUG

Mycophenolate mofetil

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

DRUG

Mycophenolic acid

Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.

Sponsors & Collaborators

  • Immune Tolerance Network (ITN)

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Daniel C. Brennan, MD · Washington University School of Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309022 on ClinicalTrials.gov